Bifeprunox versus placebo for schizophrenia

Cochrane Database of Systematic Reviews

Volumn 2016, Issue 1, 2016, Pages

  Chattopadhyay, Arka ^a   Frey, Stephen ^a   Green, Ghiselle ^a   Harkness, Alexandra ^a   Mcdermott, Alice ^a   Yates, Anna ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIFEPRUNOX; PLACEBO; BENZOXAZOLE DERIVATIVE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE;

ARTICLE; BIOSIS; CINAHL; COCHRANE LIBRARY; EMBASE; HUMAN; MEDLINE; PRIORITY JOURNAL; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SYSTEMATIC REVIEW; DRUG APPROVAL; FOOD AND DRUG ADMINISTRATION; INTENTION TO TREAT ANALYSIS; META ANALYSIS; PSYCHOLOGY; UNITED STATES; BODY WEIGHT DISORDER; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; MENTAL DETERIORATION; MENTAL HEALTH; OUTCOME ASSESSMENT; POSITIVE AND NEGATIVE SYNDROME SCALE; REVIEW; TREATMENT WITHDRAWAL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BENZOXAZOLES; DRUG APPROVAL; HUMANS; INTENTION TO TREAT ANALYSIS; PIPERAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84969545682     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD012029     Document Type: Article

References (53)

1. Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-V. American Psychiatric Association, 2013.
3. Andrew A, Knapp M, McCrone PR, Parsonage M, Trachtenberg M. Effective interventions in schizophrenia: the economic case. http://eprints.lse.ac.uk/47406/ 2012.
4. Arseneault L, Cannon M, Witton J, Murray RM. Causal association between cannabis and psychosis: examination of the evidence. British Journal of Psychiatry 2004;184(2):110-7.
5. Barbato LM, Potkin SG, Heisterberg J, Yeung PP, Shapira NA. A randomized, double-blind, placebo-controlled study of bifeprunox, a partial dopamine D2 receptor agonist, in patients with acute exacerbations of schizophrenia. Neuropsychopharmacology 2006;31:S251-2.
6. Bland JM. Statistics notes. Trials randomised in clusters. BMJ 1997;315:600.
7. Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Apercu sur la problematique des indices d'efficacite therapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacite]. Therapie 1999;54(4):405-11. [PUBMED: 10667106]
8. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophrenia Bulletin 2009;35(2):383-402.
9. Casey DE, Sands EE, Heisterberg J, Yang HM. Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study. Psychopharmacology (Berl) 2008;200:317-31.
10. Deeks J. Issues in the selection for meta-analyses of binary data. Proceedings of the 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The Cochrane Collaboration, 2000.
11. Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. Journal of General Internal Medicine 1992;7(6):623-9.
12. Dixon LB, Lehman AF, Levine J. Conventional antipsychotic medications for schizophrenia. Schizophrenia Bulletin 1995;21:567-77.
13. Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. Statistics in Medicine 2002;21:2971-80.
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
15. Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthingtond HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002;31(1):140-9.
16. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59(7):7-10.
17. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Annals of Clinical Psychiatry 2002;14(1):47-57.
18. Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. American Journal of Epidemiology 1999;149:876-83.
19. Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. Journal of Psychopharmacology 2005;19:16-27.
20. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. American Heart Journal 2005;150(6):1115-21.
21. Hersen M, Turner SM, Beidel DC. Adult Psychopathology and Diagnosis. John Wiley & Sons, 2011.
22. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
23. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
24. Hoiberg MP, Nielsen B. Antipsychotic treatment and extrapyramidal symptoms amongst schizophrenic inpatients. Nordic Journal of Psychiatry 2006;60:207-12.
25. Jauhar S, Guloksuz S, Andlauer O, Lydall G, Marques JG, Mendonca L, et al. Choice of antipsychotic treatment by European psychiatry trainees: are decisions based on evidence?. BMC Psychiatry 2012;12:27.
26. Jeffrey S. FDA finds bifeprunox unapprovable for schizophrenia. http://www.medscape.com/viewarticle/561304. Medscape, 2007.
27. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Archives of General Psychiatry 2006;63:1079-87.
28. Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health Systems, 1986.
29. Lehmann HE, Ban TA. The history of the psychopharmacology of schizophrenia. Canadian Journal of Psychiatry - Revue Canadienne de Psychiatrie 1997;42:152-62.
30. Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biological Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]
31. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. Schizophrenia Research 2005;79(2-3):231-8. [PUBMED: 15982856]
32. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. British Journal of Psychiatry 2005;187:366-71. [PUBMED: 16199797]
33. Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. Schizophrenia Bulletin 2007;33(1):183-91. [PUBMED: 16905632]
34. Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. British Journal of Psychiatry 2000;176:249-52.
35. McDonell MG, Short RA, Berry CM, Dyck DG. Burden in schizophrenia caregivers: impact of family psychoeducation and awareness of patient suicidality. Family process 2003;42:91-103.
36. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophrenia Research 2004;70:1-17.
37. Newcomer JW. Medical risk in patients with bipolar disorder and schizophrenia. Journal of Clinical Psychiatry 2006;67:25-30.
38. Newman-Tancredi A, Assie MB, Leduc N, Ormiere AM, Danty N, Cosi C. Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. International Journal of Neuropsychopharmacology 2005;8:341-56.
39. Newman-Tancredi A, Kleven MS. Pharmacology of "atypicality" of antipsychotic drugs: status and perspectives. Archives of Psychiatry and Psychotherapy 2010;4:5-11.
40. Overall JE, Gorham DR. The brief psychiatric rating scale. Psychological Reports 1962;10:799-812.
41. Pedersen CB, Mortensen PB. Family history, place and season of birth as risk factors for schizophrenia in Denmark: a replication and reanalysis. British Journal of Psychiatry 2001;179(1):46-52.
42. Rattehalli RD, Jayaram MB, Smith M. Risperidone versus placebo for schizophrenia. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD006918]
43. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatric Clinics of North America 1993;16(2):413-23.
44. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. The Cochrane Collaboration, 2008:359-83.
45. Stahl SM. Essential Psychopharmacology of Antipsychotics and Mood Stabilizers. Cambridge: Cambridge University Press, 2002.
46. Tadori Y, Kitagawa H, Forbes RA, McQuade RD, Stark A, Kikuchi T. Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912. European Journal of Pharmacology 2007;574:103-11.
47. Tandon R, Belmaker RH, Gattaz WF, Lopez-Ibor JJ Jr, Okasha A, Singh B, et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophrenia Research 2008;100:20-38.
48. Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. Health Technology Assessment 1999;3(5):1-75.
49. Valenstein M, Blow FC, Copeland LA, McCarthy JF, Zeber JE, Gillon L, et al. Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors. Schizophrenia Bulletin 2004;30:255-64.
50. van Os J, Kapur S. Schizophrenia. Lancet 2009;374(9690):635-45.
51. World Health Organization. Schizophrenia. http://www.who.int/mediacentre/factsheets/fs397/en/ 2014.
52. Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. Psychiatric Bulletin 2009;33(7):254-7.
53. Ye N, Song Z, Zhang A. Dual ligands targeting dopamine D2 and serotonin 5-HT1A receptors as new antipsychotical or anti-Parkinsonian agents. Current Medicinal Chemistry 2014;21:437-57.